Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
Najla El Jurdi, Alex Hoover, Daniel O’Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph Maakaron, Brian C. Betts, Armin Rashidi, Mark Juckett, Troy Lund, Veronika Bachanova, Margaret MacMillan, Jeffrey Miller, Paul Orchard, John Wagner, Gregory Vercellotti, Daniel Weisdorf, Kathryn Dusenbery, Stephanie Terezakis, Shernan Holtan
doi: https://doi.org/10.1101/2023.03.24.23287521
